Abstract Thu119: The Impact of Demographic and geographic factors on Mortality in Cerebrovascular Disease Patients with co-existing Metabolic Disorders: Insights from a retrospective analysis (1999-2020)

Background: Cerebrovascular disease ranks as the third leading cause of death globally, the fifth in the U.S., and a major contributor to long-term disability. Its association with metabolic disorders (MetS) is well recognized, yet mortality trends reflecting their combined impact remain underexplored Research Question: How have mortality trends in cerebrovascular disease patients with MetS varied across the U.S. population from 1999 to 2020? Methodology: A retrospective analysis using CDC-WONDER (1999-2020) examined mortality from cerebrovascular disease (ICD-10: I60-I69) with MetS (E70-E89) as a comorbidity. Joinpoint regression assessed trend disparities, with significance set at p<0.05. Results: From 1999-2020, 117,701 deaths were recorded (AAMR: 4.6, 95% CI: 4.6–4.6), with 39.7% in males and 60.3% in females. A sharp mortality rise occurred from 2018-2020 for both sexes, with mean APCs of 10.62% (females, 95% CI: 5.20–13.33) and 12.52% (males, 95% CI: 6.87–15.78). Hispanics showed a non-significant upward trend (1999-2008) but experienced a post-2018 surge (APC: 12.48%, 95% CI: 2.70–19.30). Non-Hispanics had a similar rise post-2018 (APC: 10.49%, 95% CI: 5.95–12.99). Asian/Pacific Islanders and Whites had the most pronounced increases from 2018-2020, with APCs of 16.20% (95% CI: 7.65–20.51) and 16.24% (95% CI: 11.72–18.98), respectively. While Northeast mortality trends remained stable (2006-2018), the South (Census Region 3) showed a significant increase from 2007-2018 (APC: 1.58%, 95% CI: 0.44–3.05). Conclusion: Mortality trends showed significant disparities across demographics, with a notable post-2018 surge in Asian/Pacific Islanders, Whites, and the South. These findings highlight the need for targeted interventions to address the rising burden.